human lncrna microarray v4.0  (Arraystar inc)

Journal: bioRxiv

Article Title: CRlSPR/Cas9 screening revealed BlRC6-AS1 /BlRC6 mediates abiraterone resistance via NHEJ pathway-dependent A20 degradation in prostate cancer

doi: 10.1101/2025.10.01.679907

Figure Lengend Snippet: ( A ) Schematic of CRISPR-Cas9 screens: A lentiviral sgRNA library was transduced into PC3-Cas9 cells, which were then treated with DMSO or Abiraterone, respectively. After 28 days, sgRNAs were extracted for NGS. ( B ) Box plots displaying sgRNA distribution in the experimental groups from lncRNA CRISPR-Cas9 library: D0-DMSO (baseline), D28-DMSO (vehicle control), and D28-Abiraterone (treatment). ( C and D ) Volcano plots showing depleted (red; RRA Score ≤ 0.05, -log□FC ≥ 2) and enriched (blue; RRA Score ≤ 0.05, log□FC ≥ 2) genes. Screening analysis was performed with MaGeCK RRA. ( C ) Negative selection identified 523 abiraterone resistance-associated LncRNAs and 553 essential LncRNAs. ( D ) Positive selection revealed 717 LncRNAs associated with abiraterone sensitivity and 169 essential LncRNAs. ( E ) Venn diagram showed negatively selected genes from two comparisons: Abiraterone vs Control and Control vs D0. ( F ) MAGeCK analysis results displayed a ranking of genes based on their RRA scores. ( G ) Frequency distribution of log2 fold change for all sgRNAs (top) and log2 fold change of individual sgRNAs for representative candidates (bottom). Enriched and depleted sgRNA hits were indicated by red and blue vertical bars, respectively. ( H ) The RRA score distribution plot revealed the top 10 candidate LncRNAs associated with abiraterone resistance. ( I-N ) Cell viability assays in PC3 ( I-K ) and DU145 ( L-N ) cells treated with 0-70 μM abiraterone for 48h, following transduction with either control sgRNAs or sgRNAs targeting candidate lncRNAs: RP11-1079K10.3 ( I and L ), WWTR1-AS1 ( J and M ), and RP11-49K24.4 ( K and N ). Data are shown as the mean ± SD (n = 4 biological replicates). Data were analyzed by two-way analysis of variance (ANOVA) with Dunnett’s multiple comparisons test ( I-N ).

Article Snippet: PC3-Cas9 cells (4×10 ) were transduced with either the Splicing-targeting CRISPR-Cas9 library for human lncRNAs (Addgene, Cat# 119977) or the Human genome-wide lentiviral CRISPR gRNA library version 1 (Addgene, Cat# 67989) at a multiplicity of infection (MOI) of 0.3, ensuring single gRNA integration per cell.

Techniques: CRISPR, Control, Selection, Transduction

Journal: Endocrine Connections

Article Title: lncRNA RP11-34D15.2 sponges miR-223 to promote the PGC-1α/irisin signaling pathway, contributing to increased FFA and insulin resistance in obese children

doi: 10.1530/EC-25-0028

Figure Lengend Snippet: Expression profile of lncRNA RP11-34D15.2 in WAT of obese children. (A) Volcano plot identifies upregulated (red) and downregulated (blue) lncRNAs in WAT of obese ( n = 3) versus non-obese ( n = 3) children (fold change >2.0, P < 0.05). (B) Top ten differentially expressed lncRNAs ranked by log2 (fold change). (C) Quantitative PCR (qPCR) validation of lncRNA RP11-34D15.2 expression in WAT of obese and non-obese children ( P < 0.01). (D) Positive correlation between lncRNA RP11-34D15.2 and FNDC5/irisin mRNA levels ( r = 0.603, P < 0.05). (E and F) Negative correlations between lncRNA RP11-34D15.2 and serum FFAs ( r = −0.556) or HOMA-IR ( r = −0.470) ( P < 0.05). Data: mean ± SD. ** P < 0.01.

Article Snippet: Comprehensive lncRNA profiling was performed using the Arraystar Human LncRNA Array v4.0 platform (Arraystar Inc., USA).

Techniques: Expressing, Real-time Polymerase Chain Reaction, Biomarker Discovery

Journal: Endocrine Connections

Article Title: lncRNA RP11-34D15.2 sponges miR-223 to promote the PGC-1α/irisin signaling pathway, contributing to increased FFA and insulin resistance in obese children

doi: 10.1530/EC-25-0028

Figure Lengend Snippet: lncRNA RP11-34D15.2 functions as a ceRNA by sponging miR-223-5p to upregulate PGC-1α. (A) RNAhybrid-predicted binding sites between lncRNA RP11-34D15.2 and miR-223-5p. (B) Negative correlation between lncRNA RP11-34D15.2 and miR-223-5p levels in WAT ( r 2 = 0.748, P < 0.01). (C) Luciferase reporter assay confirming direct interaction. (D and E) miR-223-5p levels in lncRNA RP11-34D15.2-overexpressing or -silenced SW872 cells. (F and G) Western blot analysis of PGC-1α protein levels in lncRNA RP11-34D15.2-modulated cells. (H) qRT-PCR analysis of PGC-1α mRNA in cells transfected with miR-223-5p mimics or inhibitor. (I) RNAhybrid-predicted binding sites between PGC-1α 3′-UTR and miR-223-5p. (J) Luciferase reporter assay validating miR-223-5p targeting of PGC-1α. Data: mean ± SD. ** P < 0.01.

Article Snippet: Comprehensive lncRNA profiling was performed using the Arraystar Human LncRNA Array v4.0 platform (Arraystar Inc., USA).

Techniques: Binding Assay, Luciferase, Reporter Assay, Western Blot, Quantitative RT-PCR, Transfection

Journal: Endocrine Connections

Article Title: lncRNA RP11-34D15.2 sponges miR-223 to promote the PGC-1α/irisin signaling pathway, contributing to increased FFA and insulin resistance in obese children

doi: 10.1530/EC-25-0028

Figure Lengend Snippet: Metabolic and molecular effects of lncRNA RP11-34D15.2 knockdown in HFD-fed C57BL/6J mice. (A) Body weight. (B) PAT mass. (C and D) Serum insulin and FFA levels. (E) Serum irisin levels. (F and G) qRT-PCR analysis of lncRNA RP11-34D15.2 and miR-223-5p mRNA in PAT. (H and I) Western blot analysis of PGC-1α, FNDC5/irisin, CPT-1, and UCP-1 protein levels. (J and K) Western blot analysis of IRS-1 protein levels. FFA: free fatty acids. Data: mean ± SD. * P < 0.05; **: P < 0.01.

Article Snippet: Comprehensive lncRNA profiling was performed using the Arraystar Human LncRNA Array v4.0 platform (Arraystar Inc., USA).

Techniques: Knockdown, Quantitative RT-PCR, Western Blot